It is made available under a CC-BY-ND 4.0 International license .

| 1 | A multiplex serological assay for the characterization of IgG immune response to SARS- |
|----|---|
| 2 | CoV-2 |
| 3 | |
| 4 | Etienne Brochot ^{a,b*} , Vianney Souplet ^{c*} , Pauline Follet ^c , Pauline Ponthieu ^c , Christophe Olivier ^c , |
| 5 | Gaël Even ^d , Christophe Audebert ^d , Rémi Malbec ^d |
| 6 | |
| 7 | ^a Department of Virology, Amiens University Medical Center, Amiens, France |
| 8 | ^b Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University |
| 9 | of Picardie, France |
| 10 | ^c Innobiochips, 70 rue du Dr Yersin, 59120 Loos, France |
| 11 | ^d GD Biotech, 3595 Route de Tournai, 59501 Douai, France |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| | |
| 18 | |
| 19 | *Corresponding authors: |
| 20 | Etienne Brochot, <u>Brochot.Etienne@chu-amiens.fr</u> ; Vianney Souplet |
| 21 | vianney.souplet@innobiochips.fr |
| 22 | |

1

It is made available under a CC-BY-ND 4.0 International license .

23 Abstract

Background: In the fight against SARS-COV-2, the development of serological assays based on
different antigenic domains represent a versatile tool to get a comprehensive picture of the immune
response or differentiate infection from vaccination beyond simple diagnosis.

27 *Objectives:* Here we use a combination of the Nucleoprotein (NP), the Spike 1 (S1) and Spike 2

28 (S2) subunits, and the receptor binding domain (RBD) and N-terminal domain (NTD) of the Spike

29 antigens from the Syrius-CoViDiag® multiplex IgG assay, to follow the immune response to

30 SARS-CoV-2 infection over a long time period and depending on disease severity.

Results: Using a panel of 209 sera collected from 61 patients up to eight months after infection, we observed that most patients develop an immune response against multiple viral epitope, but anti-S2 antibodies seemed to last longer. For all the tested IgGs, we have found higher titers for hospitalized patients than for non-hospitalized ones. Moreover the combination of the five different IgG titers increased the correlation to the neutralizing antibody titers than if considered individually.

37 Conclusion: Multiplex immunoassays have the potential to improve diagnostic performances, 38 especially for ancient infection or mild form of the disease presenting weaker antibody titers. Also 39 the combined detection of anti-NP and anti-Spike-derived domains can be useful to differentiate 40 vaccination from viral infection and accurately assess the antibody potential to neutralize the virus.

- 41
- 42

43 Key words: SARS-CoV-2, COVID-19, Serological assays, Multiplexing, IgG profile

- 44
- 45

It is made available under a CC-BY-ND 4.0 International license .

46 **1. Introduction**

Since its first detection in Wuhan (China) in December 2019, the Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) has rapidly spread to reach other countries worldwide as
the coronavirus 2019 disease (COVID-19) became pandemic (1).

50 The virion has a nucleocapsid composed by genomic RNA and phosphorylated 51 Nucleocapsid (NP) protein, which is buried inside a phospholipid bilayer and covered by the Spike 52 proteins trimmers (S) that gives the CoVs their crown-like appearance on which their names are 53 based. The S protein has two subunits, the Spike 1 (S1) which contains the receptor-binding 54 domain (RBD) and N-terminal domain (NTD) and the Spike 2 (S2) (2). The choice of the antigenic 55 domain is important, as it must be specific to the SARS-CoV-2 for discrimination against other 56 hCoVs for example, and sensitive enough so infection would not be missed (Brochot et al., 2020). 57 Also, anti-RBD antibodies are known to play a role in patients protection as this domain is used by the virus to penetrate host cells (4). Most commercial serological assays have demonstrated 58 59 satisfying performances in terms of diagnostic sensitivity and specificity, based on one of those 60 main different antigenic domains (5,6). However, the combination of different immunogenic 61 antigens can give a more comprehensive picture of the humoral response strength and diversity 62 (7-9) while maintaining elevated diagnostic performances (10,11). In multiplex assays, positivity thresholds can be adjusted to compensate for the use of antigenic domains more conserved between 63 64 coronaviruses (12). Moreover, as vaccines are based on the Spike protein, the additional detection 65 of anti-NP antibodies allows to differentiate viral infection from vaccination.

66 This study reports the design and use of the Syrius-CoViDiag[®] multiplex IgG assay for the 67 characterization of the immune response against over time, depending on disease severity, and in 68 perspective of neutralizing antibody titers.

It is made available under a CC-BY-ND 4.0 International license .

69 2. Material and Methods

70 2.1. Study design and cohort

71 The study was conducted at Amiens University medical Center (France). Samples were 72 derived from de-identified excess serum specimens. The demographic information of the patients 73 are available in Table 1. The study was approved by the institutional review board of the Amiens 74 University Medical Center (number PI2020 843 0046, 21 April 2020). 75 Briefly, we used n=209 samples collected between March and April 2020 from n=61 patients (27 hospitalized patients and 34 non-hospitalized patients) with PCR-confirmed SARS-CoV-2 76 77 infections to perform immunoassay and virus seroneutralization test as already described in Aubry 78 et al., 2021. All samples have been tested according to manufacturer's instruction on the SirYus-79 CoViDiag[®] serological assay and the raw results are available in supplementary data.

80

81 Table 1. Cohort Characteristics.

| Number of patients | 61 |
|---------------------------------|---|
| Female | 36 |
| Male | 25 |
| Age (Years): Median Range | 74 26-98 |
| >65 years | 41 |
| Hospitalized patients | 27 |
| Nonhospitalized patients | 34 |
| Immunocompromised patients | 6 (2 kidney transplant, 2 bone marrow transplant, 2 chemotherapy) |
| | |

It is made available under a CC-BY-ND 4.0 International license .

| Number of samples (days post-PCR) 0-59 60-119 120-179 ≥180 | 52 49 49 59 |
|---|----------------------|
| Number of patients (days post-PCR) 0-59 60-119 120-179 ≥180 | 50 36 42 46 |

82

83 2.2. Serological assay

84 The SirYus-CoViDiag® multiplex immunoassay targets IgG antibodies against five different 85 antigens of the virus: NP, S1, S2, RBD, and NTD (Fig. 1). Note that the S1 and NP antigens have 86 been printed in dot replicates in the shape of an "S" and "N" letters, respectively. This design 87 allows for quick visual interpretation of seropositivity and vaccination status. The results have 88 been automatically delivered using the SciReader® plate reader (Scenion GmbH) and associated 89 analysis software, and an algorithm combining different cut-offs for the different antigens 90 according to the manufacturer instructions. The spot mean signal intensity (MSI) was calculated 91 as the average pixel value inside the spot perimeter minus the local background around the spot as 92 described in Malbec et al., 2020. When multiplexing, the positivity thresholds can be adjusted with 93 the number of different IgG antibodies detected. As NP and S2 antigens are more conserved 94 between coronaviruses, SARS-CoV-2 IgG positivity is declared when a single one of them gives 95 a signal over 40 MSI. However when NP and S2 antibodies are concomitantly present, the cut-off 96 is adjusted to 20 MSI. For S1, RBD, and NTD antibodies a cut-off of 10 MSI is applied for SARS-97 CoV-2 positivity. Based on this algorithm, the test has been accredited by the French National 98 Reference Center (CNR) in August 2020. On a reference cohort of 48 sera from patients positive 99 to Covid-19 and 48 sera from patients negative to Covid-19. 14 days post symptoms, the diagnostic 100 sensitivity was 90 %. The diagnostic specificity was 100 %.

It is made available under a CC-BY-ND 4.0 International license .

101

Figure 1. Full well pictures pictures obtained with the microplate reader (SciReader[®]) or with a phone camera (in insert) after incubation with the CoViDiag[®] assay. (A) Positive sample presenting antibodies against the Nucleopcapside (NP), Spike 1 (S1), N-terminal domain (NTD) and Receptor binding domain (RBD) of the Spike protein, or Spike 2 (S2) antigens. (B) Negative sample with positive control on the edges. Scale bars correspond to 1 mm.

107

108 2.3. Statistical analysis

For the statistical analysis, Student's test was used to test the relationship between different categorical variables and the difference in antibody MSI between hospitalized and nonhospitalized groups of patients. Spearman's rank Correlation test was used to test the correlation between different antibody MSI and dilution factor for the neutralization assay. The general significance level was set at a p-value below 0.05. All analyses were performed using packages stats from the R statistical computing program v. 3.6.1 (Date of release 07/05/2019).

115

116 **3. Results**

117 *3.1. Evolution of the IgG profile over time*

Using the SirYus-CoViDiag® assay on 209 serum samples, the seropositivity stayed stable
around 90 % for 6 months after an initial positive SARS-CoV-2 RT–PCR, before decreasing to
83.1 % between six and eight months (Fig. 2A).

121

Figure 2. Evolution of the IgG profile over time. (A) Percentage of patients CoViDiag positive to antiNP, anti-S1, anti-S2, anti-RBD, and anti-NTD IgG antibodies and (B) associated average IgG titers.

It is made available under a CC-BY-ND 4.0 International license .

- 124 Positivities for each IgG considered individually are also reported based on the cut-offs set
- 125 by the manufacturer. 54.1 % (n=113/209) samples were concomitantly positives for anti-NP, anti-
- 126 S1, anti-S2 and anti-RBD antibodies and 9.1 % (n=19/209) for all 5 antibodies. 4.3 % (n=9/209)
- 127 samples were positives for a single antibody (n=6 for anti-NP, n=2 for anti-S1 and n=1 for anti-
- 128 S2) (Table 2). 80.9 % (n=169/209) samples were positives to anti-NP antibodies, allowing
- 129 potential differentiation of infection from vaccination.
- 130

131 Table 2. Prevalence of the profile of IgG immune response. Percentage of positivity for antibodies

| 132 | against differen | nt antigens or c | combinaison of antigens. |
|-----|------------------|------------------|--------------------------|
| - | 0 | 0 | 8 |

| | Ν | % Seroprevalence |
|----------------------------|-----|------------------|
| Samples | 209 | |
| Single antibody | | |
| NF | 6 | 2.9 |
| SI | 2 | 1.0 |
| S2 | 2 1 | 0.5 |
| RBD | 0 | 0 |
| NTD | 0 | 0 |
| Total | 1 9 | 4.3 |
| Combinaison of antibodies* | | |
| NP+S2 | 2 5 | 2.4 |
| NP+S1+S2 | 2 5 | 2.4 |
| NP + SI + RBD | 6 | 2.9 |
| NP+S2+RBD | 13 | 6.2 |
| S1+S2+RBD | 0 6 | 2.9 |

It is made available under a CC-BY-ND 4.0 International license .

| NP+S1+S2+RBD | 113 | 54.1 |
|------------------|-----|------|
| NP+S1+S2+RBD+NTD | 19 | 9.1 |

| * For clarity purpose, only most common combinaisons with >2% seroprevalence are reported. |
|---|
| |
| The kinetics of the IgG serum antibody response to individual antigens are presented in |
| Fig. 2B. Average MSIs have been calculated for all samples depending on the time post RT-PCR |
| to SARS-CoV-2. The anti-NP and anti-NTD antibody responses were the first to decrease, as |
| their MSI started to decline after just two months (-0.9 $\%$ and -8.1 $\%$ between two and four |
| months, respectively). The anti-S1 and anti-RBD response peaked after four months, before |
| significatively decreasing over time (-7.8 % and -13 % between four and six months, |
| respectively). The anti-S2 antibody response was the most delayed, with a peak level reached |
| between four and six months. The different dynamics observed show the interest of detecting |
| IgG response against multiple immunogenic domains to maintain elevated diagnostic sensitivity, |
| especially long after infection. |
| |
| 3.2. IgG profile depending on the disease severity |
| Then we have investigated the ability for the multiplex assay to differentiate hospitalized |
| (severe cases) versus non hospitalized (mild cases) patients, based on the first sample collected |
| for each of the 61 patients in the early convalescent phase of the disease. For all five |
| immunogenic domains, the MSI, corresponding to the levels of antibody are plotted in Fig. 3, |
| depending on disease severity. For each given antigen, we have observed a trend of greater |
| antibody response for hospitalized patients (MSI: NP= 56.5; S1=49.1; S2=59.4; RBD=54.8; |
| NTD=11.8; Average=46.3) compare to non-hospitalized ones (MSI: NP= 51.8; S1=37.4; |
| S2=49.2 ; RBD=47.1 ; NTD=4.3 ; Average=37.9). However, the differences were not statistically |
| |

It is made available under a CC-BY-ND 4.0 International license .

155 different (p-value > 0.05, see supplementary Table 1).

156

Figure 3. IgG profile depending on disease severity outcome. Distribution of the different IgG titers based on the MSI, considered individually, or altogether (average) for hospitalized (n=25) and nonhospitalized patients (n=34) just after infection.

160

161 *3.3. Correlation between IgG profile and neutralizing antibody titers.*

162 Finally, we have evaluated the ability for the correlation between the different IgG levels 163 response and the seroneutralization potential of the samples. For all five immunogenic domains, 164 the mean intensity, corresponding to the levels of antibody response are plotted in Fig. 4 165 depending on the highest dilution of serum resulting in a 90 % decrease in infectivity. As 166 expected, the best correlation (see supplementary Table 2) between individual IgGs and neutralizing antibody response was obtained for anti-RBD antibodies ($r^2=0.72$). The correlation 167 was very similar between anti-S1 ($r^2=0.67$) and anti-S2 ($r^2=0.66$) antibodies. However Anti-NP 168 $(r^2=0.59)$ and anti-NTD $(r^2=0.47)$ antibodies titers were less correlated with the neutralizing 169 170 antibody titers. Interestingly, the combination of the 5 different antibody responses, allowed to 171 slightly increase the correlation to $(r^2=0.74)$.

172

173 Figure 4. Correlation of the different IgG titers with serum neutralization titers. IgGs titers are based 174 on the MSI considered individually, or altogether (average). Neutralizing antibody titers are based on the 175 serum dilution factor to neutralize 90 % of infected cells.

176

177 **4. Discussion**

It is made available under a CC-BY-ND 4.0 International license .

178 In a previous study based on the same set of sample, we have found equivalent to improved 179 diagnostic performances, especially for ancient infections, for the CoViDiag® multiplex IgG assay compare to other IgG commercial serological assays (13). Is is now generally admitted that 180 181 antibody levels are weaker for asymptomatic and mild form of the disease and can decrease over 182 time (8). Hence in the present work, we have investigated the detailed profile of the IgG immune 183 response over an eight months period in a multiplex assay, using samples of hospitalized and 184 non-hospitalized patients. Then we have compared the results with neutralizing antibody levels. 185 We have observed that most patients develop a global immune response against multiple 186 immunogenic domains. Even over a 8 months period, more than a half of the samples were 187 positives to anti-NP, anti-S1, anti-S2, and anti-RBD antibodies, concomitantly. Those result 188 confirm the possibility to develop serological assays based on different antigens. Anti-NTD 189 antibodies are more scarce but most patients SARS-CoV-2 infected develop antibodies against 190 the NP antigen allowing potential differentiation of infection from vaccination. 191 As expected, the different IgGs titers decreased over time, but with different dynamics. 192 Elevated levels of anti-S2 seem to last longer. Therefore the detection of anti-S2 antibodies may 193 be of interest to maintain elevated diagnostic sensitivity longer after infection. The evolution of 194 anti-S1 and anti-RBD titers is very similar, as RBD constitutes a domain of the Spike 1 protein. 195 For all the tested IgGs, we have found higher titers for hospitalized patients than for non-196 hospitalized ones. However, the differences were not statistically significant as a large number of 197 patients had no immune response detected for individual antigens, independently of the disease 198 severity.

199 It is noteworthy that most commercial assays performances have been established at the 200 beginning of the epidemic, when samples from hospitalized patients were the easier to collect.

10

It is made available under a CC-BY-ND 4.0 International license .

For people presenting a weaker immune response, multiplexing allows to test for extra domains
that may help to slightly increase diagnostic sensitivity without compromising for diagnostic
specificity.

Except for anti-NTD antibodies, all different IgGs titers were positively correlated with the neutralizing antibody titers. This result is not surprising considering our previous observation showing that anti-NP, anti-S1, anti-S2, and anti-RBD antibodies are concomitantly present in patient's sera. As expected, the best correlation for individual antigen is obtained for antibodies targeting the virus RBD domain which is known to be involved in the penetration of the cells by the virus. However the average combination of all five antigens slightly increased the

210 correlation, strengthening the interest for multiplexing.

211

212 **5.** Conclusion

213 Beyond the diagnosis of SARS-COV-2 infection, tools delivering a global picture of the 214 patients' immune response may also be of interest to improve the management and care of the 215 patients and populations. Our results show that elevated IgGs titers against multiple viral epitope 216 may be more characteristic of symptomatic patients, and correlates well with neutralizing 217 antibodies. We recommend using assays targeting IgGs for the evaluation of a long lasting 218 population protection and collective immunity. Furthermore, multiplexed assays have the 219 potential to slightly increase diagnostic performances, especially for ancient or weak infections 220 and be more representative of immune protection. For future epidemical studies, as the 221 vaccination based on the Spike protein progresses, multiplex serological assays may also help to 222 differentiate vaccination from viral infection.

223

It is made available under a CC-BY-ND 4.0 International license .

224 Funding

225 Laboratory's own resources

226

227 **Declaration of competing interest**

- 228 Authors Rémi Malbec, Gaël Even and Christophe Audebert are employees of GD Biotech, while
- 229 Pauline Ponthieu, Pauline Follet, Vianney Souplet and Christophe Olivier are employees of
- 230 Innobiochips, providing the CoViDiag® assay kits for this study.

231

232 **References**

- Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. mars 2020;579(7798):270-3.
- Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune
 responses. Journal of Medical Virology. 2020;92(4):424-32.
- Brochot E, Demey B, Touze A, Belouzard S, Dubuisson J, Schmit J-L, et al. Anti-Spike,
 anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 hospitalized patients and
 asymptomatic carriers [Internet]. Infectious Diseases (except HIV/AIDS); 2020 mai [cité 20
 mai 2020]. Disponible sur: http://medrxiv.org/lookup/doi/10.1101/2020.05.12.20098236
- Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The
 receptor binding domain of the viral spike protein is an immunodominant and highly
 specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 11 juin
 2020;5(48):eabc8413.
- 5. Brochot E, Demey B, Handala L, François C, Duverlie G, Castelain S. Comparison of
 different serological assays for SARS-CoV-2 in real life. J Clin Virol. sept
 2020;130:104569.
- Tuaillon E. Detection of SARS-CoV-2 antibodies using commercial assays and
 seroconversion patterns in hospitalized patients. medRxiv. 12 mai
 2020;2020.05.04.20090027.
- Coste AT, Jaton K, Papadimitriou-Olivgeris M, Greub G, Croxatto A. Comparison of
 SARS-CoV-2 serological tests with different antigen targets [Internet]. Infectious Diseases
 (except HIV/AIDS); 2020 juill [cité 20 juill 2020]. Disponible sur:
- 255 http://medrxiv.org/lookup/doi/10.1101/2020.07.09.20149864

It is made available under a CC-BY-ND 4.0 International license .

| 256 257 258 | 8. | Grossberg AN, Koza LA, Ledreux A, Prusmack C, Krishnamurthy HK, Jayaraman V, et al. A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients. Nat Commun. déc 2021;12(1):740. |
|--------------------------|---|---|
| 259 260 261 262 | 9. | Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity [Internet]. Infectious Diseases (except HIV/AIDS); 2020 juin [cité 31 août 2020]. Disponible sur: http://medrxiv.org/lookup/doi/10.1101/2020.06.03.20121525 |
| 263 264 265 266 | 10. | de Assis RR, Jain A, Nakajima R, Jasinskas A, Felgner J, Obiero JM, et al. Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray [Internet]. Immunology; 2020 avr [cité 10 juin 2020]. Disponible sur: http://biorxiv.org/lookup/doi/10.1101/2020.04.15.043364 |
| 267 268 269 270 | 11. | Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, et al. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. Journal of Virological Methods. 1 févr 2021;288:114025. |
| 271 272 273 | 12. | Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host & Microbe. avr 2020;27(4):671-680.e2. |
| 274 275 276 | 13. | Aubry A, Demey B, François C, Duverlie G, Castelain S, Helle F, et al. Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis. 2021;8. |
| 277 278 279 | 14. | Malbec R, Kimpston-Burkgren K, Vandenkoornhuyse E, Olivier C, Souplet V, Audebert C, et al. Agrodiag PorCoV: A multiplex immunoassay for the differential diagnosis of porcine enteric coronaviruses. Journal of Immunological Methods. août 2020;483:112808. |
| 280 | | |
| 281 | 1 Supporting information captions | |
| 282 | 2 Supplementary Table 1. Mean Signal Intensity (MSI) of the antibody response to different antigens for | |
| 283 | hospitalized and non-hospitalized patients. | |
| 204 | a | |

284 **Supplementary Table 2.** Correlation between individual antigen titers and neutralizing antibody titers.







